Frontage, a full service contract research organization (CRO), has named Michael Willett, PharmD., RAC, as president of its clinical business unit.
Dr. Willett is a seasoned industry professional with more than 25 years of experience in clinical research involving new chemical entities, biologics, biosimilars, medicines targeted for new therapeutic uses (505(b)(2) programs), consumer health, and generic drugs. In 1994, Dr. Willett established Advanced Biomedical Research Inc. (ABR), a Phase I-II clinical CRO, which was later acquired by Frontage in 2008. He left Frontage in 2009 to start a clinical and research consultancy, Ready Clinical LLC, where he provided strategic regulatory, clinical and pharmacokinetic consultation and analysis services in support of early phase clinical development programs.
Dr. Willett has been involved in fast-track programs with drugs treating rare diseases and has performed site audits, best practice evaluations and training to academic and non-academic investigative sites. He has been a sub-investigator on over 400 Phase I-II clinical trials involving a wide range of compounds and has been involved in regulatory submissions for multiple new product approvals.
“I am very excited to work with Michael once again as he leads our clinical operations. He is an exceptional scientific, operational and regulatory expert with more than two decades of thought leadership in pharmaceutical clinical research. I believe his leadership skills will take our clinical business to greater levels of success and improved performance for our valued clients,” said Song Li, chief executive officer, Frontage Laboratories
